Edition:
United States

Sorrento Therapeutics Inc (SRNE.OQ)

SRNE.OQ on NASDAQ Stock Exchange Capital Market

2.35USD
12 Dec 2017
Change (% chg)

$-0.05 (-2.08%)
Prev Close
$2.40
Open
$2.45
Day's High
$2.55
Day's Low
$2.35
Volume
151,244
Avg. Vol
162,326
52-wk High
$6.05
52-wk Low
$1.50

Latest Key Developments (Source: Significant Developments)

Sorrento Therapeutics Enteres Into Securities Purchase Agreement
Monday, 11 Dec 2017 09:45am EST 

Dec 11 (Reuters) - Sorrento Therapeutics Inc ::SORRENTO THERAPEUTICS SAYS ON DEC 11, CO ENTERED INTO SECURITIES PURCHASE AGREEMENT - SEC FILING.SORRENTO THERAPEUTICS SAYS AGREED TO ISSUE, SELL TO PURCHASERS, IN A PRIVATE PLACEMENT, CONVERTIBLE PROMISSORY NOTES IN OF $50 MILLION.  Full Article

Sorrento Therapeutics says co entered into an at market issuance sales agreement with B. Riley FBR as sales agent
Thursday, 9 Nov 2017 09:27am EST 

Nov 9 (Reuters) - Sorrento Therapeutics Inc :Sorrento Therapeutics - ‍On Nov. 9, 2017, co entered into an at market issuance sales agreement with B. Riley FBR, Inc., as sales agent - SEC Filing​.Sorrento Therapeutics Inc - ‍ Pursuant to sales agreement, co may offer and sell through agent up to $100 million in shares of common stock​.  Full Article

Sorrento Therapeutics files for mixed shelf of upto $350 mln
Thursday, 9 Nov 2017 09:10am EST 

Nov 9 (Reuters) - Sorrento Therapeutics Inc :Sorrento Therapeutics Inc files for mixed shelf of upto $350 million - SEC filing‍​.  Full Article

Sorrento Therapeutics- ‍Terminated​ deal with Semnur Pharma to purchase all its issued and outstanding equity
Friday, 6 Oct 2017 05:44pm EDT 

Oct 6 (Reuters) - Sorrento Therapeutics Inc :Sorrento Therapeutics - ‍ co, unit Semnur Pharmaceuticals terminated​ deal by which unit would, purchase all of issued and outstanding equity of Semnur.  Full Article

Sorrento Therapeutics files for resale by selling stockholders of up to 754K shares of common stock - SEC filing‍​
Thursday, 5 Oct 2017 06:34am EDT 

Oct 5 (Reuters) - Sorrento Therapeutics Inc : :Sorrento Therapeutics Inc - files for resale by selling stockholders of up to 754,930 shares of common stock - SEC filing‍​.  Full Article

FDA acknowledges receipt of Sorrento Therapeutics Inc's NDA for Ztlido
Tuesday, 12 Sep 2017 06:01am EDT 

Sept 12 (Reuters) - Sorrento Therapeutics Inc :Fda acknowledges receipt of Sorrento Therapeutics Inc, NDA for Ztlido; PDUFA date set for February 28, 2018.Sorrento Therapeutics Inc - ‍PDUFA goal date for completion of FDA'S review of SCILEX NDA is set for February 28, 2018​.  Full Article

Sorrento Therapeutics submits NDA for Ztlido
Tuesday, 29 Aug 2017 06:00am EDT 

Aug 29 (Reuters) - Sorrento Therapeutics Inc :Sorrento Therapeutics Inc submits NDA for Ztlido next-generation lidocaine patch.Unit resubmitted NDA and responded to all of FDA comments related to initial NDA submission for its lead product candidate, Ztlido.If approved, Ztlido could be ready for commercial launch in U.S. in 2018.Company intends to submit a marketing authorization application for Ztlido in Europe in Q4 of this year.  Full Article

Sorrento Therapeutics says FDA authorizes co's IND for RTX
Thursday, 29 Jun 2017 12:22pm EDT 

June 29 (Reuters) - Sorrento Therapeutics Inc ::Sorrento Therapeutics announced FDA authorization of IND to commence clinical trial of RTX in intractable cancer pain.Intends to initiate Phase 1b clinical trial of RTX administered by epidural injection for treatment of cancer associated pain.  Full Article

Semnur Pharmaceuticals announces successful phase 1/2 trial for its lead product, SP-102
Monday, 26 Jun 2017 07:17am EDT 

June 26 (Reuters) - Semnur Pharmaceuticals Inc: :trial also showed that adverse events were comparable between two treatments.Semnur pharmaceuticals inc announces successful phase 1 / 2 trial in patients with radicular pain for its lead product, SP-102.trial was conducted in patients with radicular pain, achieved its primary pharmacokinetic endpoint.announced successful phase 1 / 2 pharmacokinetic bridging trial of lead product SP-102.  Full Article

SORRENTO THERAPEUTICS ANNOUNCES DISMISSAL OF LAWSUITS
Wednesday, 14 Jun 2017 02:29pm EDT 

June 14 (Reuters) - Sorrento Therapeutics Inc :SORRENTO THERAPEUTICS ANNOUNCES DISMISSAL OF LAWSUITS.SORRENTO THERAPEUTICS INC SAYS DISMISSAL OF ALL CLAIMS AGAINST SORRENTO AND ITS DIRECTORS CONTAINED IN LAWSUITS BROUGHT BY WILDCAT LIQUID ALPHA, LLC.  Full Article

BRIEF-Sorrento Therapeutics Enteres Into Securities Purchase Agreement

* SORRENTO THERAPEUTICS SAYS ON DEC 11, CO ENTERED INTO SECURITIES PURCHASE AGREEMENT - SEC FILING